A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Trial Profile

A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2015

At a glance

  • Drugs Verucerfont (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jun 2015 According to a Neurocrine Biosciences media release, this trial was halted by the company out of an abundance of caution as a result of recent unexpected preclinical findings. The FDA has placed partial clinical hold on the NBI 77860 clinical development program.
    • 08 Jun 2015 According to a Neurocrine Biosciences media release, status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top